Pfizer has completed a global licensing agreement with 3SBio, excluding China, to develop, manufacture, and commercialise SSGJ-707 – a bispecific antibody targeting PD-1 and VEGF.

輝瑞已完成與三生製藥（3SBio）的全球許可協議，不包括中國，以開發、生產和商業化SSGJ-707——一種針對PD-1和VEGF的雙特異性抗體。

The therapy was developed using 3SBio’s proprietary CLF2 platform and adds to Pfizer’s expanding oncology portfolio, particularly in the field of immuno-oncology.

該療法採用三生製藥的專有CLF2平臺開發，爲輝瑞不斷擴展的腫瘤學產品組合增添了新的力量，特別是在免疫腫瘤學領域。

The agreement strengthens Pfizer’s position in cancer research, enabling it to explore new combination treatments across several key cancer types. SSGJ-707 is currently being studied in China in clinical trials for conditions including non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumours.

該協議加強了輝瑞在癌症研究領域的地位，使其能夠探索多種關鍵癌症類型的新聯合治療方法。 SSGJ-707 目前正在中國進行包括非小細胞肺癌 (NSCLC)、轉移性結直腸癌和婦科腫瘤在內的臨牀試驗研究。

Interim Phase 2 results for advanced NSCLC have shown encouraging outcomes and were presented at the recent ASCO Annual Meeting..

針對晚期非小細胞肺癌的中期第二階段結果顯示出令人鼓舞的成果，並在最近的美國臨牀腫瘤學會年會上公佈。

Pfizer plans to produce the drug substance for SSGJ-707 at its facility in Sanford, North Carolina, and the drug product in McPherson, Kansas.

輝瑞計劃在其位於北卡羅來納州桑福德的工廠生產SSGJ-707的藥物成分，並在堪薩斯州麥克弗森生產藥物製劑。

As part of the agreement, 3SBio will receive a payment of $1.25 billion. Pfizer will also invest $100 million in 3SBio through an equity transaction. The deal includes an option for Pfizer to obtain exclusive rights for SSGJ-707 in China, which could result in additional payments of up to $150 million if the option is exercised..

根據協議，三生製藥將獲得12.5億美元的付款。輝瑞還將通過股權交易向三生製藥投資1億美元。該協議包括輝瑞在中國獲得SSGJ-707獨家權利的選項，如果行使該選項，可能會導致高達1.5億美元的額外付款。

The development plan includes global trial sites, with an initial focus on launching Phase 3 studies for NSCLC and other solid tumours in the United States.

開發計劃包括全球試驗基地，初步重點是在美國啓動針對非小細胞肺癌和其他實體瘤的第三階段研究。

Source: pfizer.com

來源：pfizer.com